Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Feb 28, 2019 (8 years ago)

BuPROPion Hydrochloride Extended-Release Tablets

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed Dissolution Specifications; 9-monthstability timepoint

Cause type: Dissolution failure

The tablet or capsule did not dissolve within specification. Dissolution controls how much drug the body absorbs; a failure can change the effective dose. All dissolution failure recalls.

What was recalled

BuPROPion Hydrochloride Extended-Release Tablets, USP (XL) 150 mg, a) 30 count (NDC 59746- 758-30) & b) 90 count (NDC 59746-758-90) bottles, Rx only, Manufactured b Jubilant Generis Ltd, Roorkee, India, Marketed by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD

Affected NDC 59746-0758-90

Compare with the code on your package — it is the most precise check available.

Drug: Bupropion Category: Mental Health Medication

Recalling firm
Jubilant Cadista Pharmaceuticals, Inc.
NDC code
59746-758-90
Origin
MD, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0519-2019 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Bupropion recalls

See all

Other recalls by Jubilant Cadista Pharmaceuticals, Inc.

All 2019 recalls
Class II · Moderate risk

Irbesartan Tablets

Failed Dissolution Specifications

Terminated Dissolution failure Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-447-90 D-1294-2022
Class II · Moderate risk

Irbesartan Tablets

Failed dissolution specifications.

Terminated Dissolution failure Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-448-90 D-1293-2022